Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.89
- Piotroski Score 5.00
- Grade Buy
- Symbol (RLAY)
- Company Relay Therapeutics, Inc.
- Price $5.95
- Changes Percentage (1.71%)
- Change $0.1
- Day Low $5.66
- Day High $6.00
- Year High $12.14
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $19.00
- High Stock Price Target $25.00
- Low Stock Price Target $16.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.63
- Trailing P/E Ratio -3
- Forward P/E Ratio -3
- P/E Growth -3
- Net Income $-341,973,000
Income Statement
Quarterly
Annual
Latest News of RLAY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jets vs. Texans 'TNF' picks, props: Target this same-game parlay
Texans face a setback with star receiver Stefon Diggs out for the season due to ACL injury. With depleted options, running back Mixon becomes a focal point for offense against Jets. Analyzing potentia...
By New York Post | 5 days ago -
Football Parlay Friday Week 8: Georgia and four other underdogs that have a shot to win
It's Football Parlay Friday with college football games offering value bets. Despite last week's close losses, the season record stands at 10-67, +$2.60, +1.7% ROI....
By The New York Times | 2 weeks ago -
Broncos vs. Saints Week 7 same-game parlay: 'TNF' odds,...
Sean Payton, former Saints head coach, returns to New Orleans as Denver's new head coach. Rookie QBs Nix and Rattler face off with injuries impacting the Saints. Broncos look to capitalize on their st...
By New York Post | 2 weeks ago
